The company's oncology portfolio is currently bolstered by lucrative drugs like Imbruvica and Venclexta. Its neuroscience portfolio, including drugs like Vraylar and Botox Therapeutic, is also ...

This exemption stands as a notable advantage for the company’s cancer therapy drug, Venclexta, potentially preserving its competitive positioning and pricing dynamics in a challenging environment.

AbbVie’s leukemia drug Venclexta generated revenues of $691 million in the reported quarter, reflecting 8.3% growth. The company markets Venclexta in collaboration with Roche RHHBY.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

By inhibiting BCL-2, Venclexta is designed to help reinitiate apoptosis in cancer cells. Venclexta is being co-developed by AbbVie and Roche. In the United States, it is jointly commercialized by ...

VENCLEXTA is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the ...

VENCLEXTA targets the BCL-2 protein and works to help restore the process of apoptosis. VENCLEXTA is being developed by AbbVie and Roche.

VENCLEXTA and other medicines may affect each other causing serious side effects. Do not start new medicines during treatment with VENCLEXTA without first talking with your healthcare provider.